Asia Pacific preventive vaccines market will grow by 7.9% annually with a total addressable market cap of $217.46 billion over 2023-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.
Highlighted with 59 tables and 54 figures, this 141-page report “Asia Pacific Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• mRNA Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pneumococcal Disease
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Human Papilloma Virus
• COVID-19
• Other Diseases
By Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
By Patient, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Vaccine Type, Disease, and Administration over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 27
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 37
2.4 Emerging Opportunities and Market Trends 40
2.5 Porter’s Fiver Forces Analysis 44
3 Segmentation of Asia Pacific Market by Vaccine Type 48
3.1 Market Overview by Vaccine Type 48
3.2 Live/Attenuated Vaccines 50
3.3 Inactivated Vaccines 51
3.4 Subunit Vaccines 52
3.5 Toxoid Vaccines 53
3.6 Conjugate Vaccines 54
3.7 mRNA Vaccines 55
3.8 Recombinant Vector Vaccines 56
3.9 Other Vaccines 57
4 Segmentation of Asia Pacific Market by Disease 58
4.1 Market Overview by Disease 58
4.2 Pneumococcal Disease 60
4.3 Poliovirus 61
4.4 Hepatitis 62
4.5 Influenza 63
4.6 Measles, Mumps, and Rubella (MMR) 64
4.7 Varicella 65
4.8 Human Papilloma Virus 66
4.9 COVID-19 67
4.10 Other Diseases 68
5 Segmentation of Asia Pacific Market by Administration 69
5.1 Market Overview by Administration 69
5.2 Intramuscular Route 71
5.3 Subcutaneous Route 72
5.4 Oral Route 73
5.5 Intravenous Injection 74
5.6 Other Administration Routes 75
6 Segmentation of Asia Pacific Market by Patient 76
6.1 Market Overview by Patient 76
6.2 Pediatric Vaccines 78
6.3 Adult Vaccines 80
7 Asia-Pacific Market 2022-2032 by Country 82
7.1 Overview of Asia-Pacific Market 82
7.2 Japan 85
7.3 China 89
7.4 Australia 93
7.5 India 96
7.6 South Korea 99
7.7 Rest of APAC Region 102
8 Competitive Landscape 104
8.1 Overview of Key Vendors 104
8.2 New Product Launch, Partnership, Investment, and M&A 107
8.3 Company Profiles 108
AstraZeneca plc 108
Bavarian Nordic A/S 110
China National Biotec Group Company Ltd. 113
CSL Ltd. 115
Daiichi Sankyo Co. Ltd 117
Emergent BioSolutions Inc. 119
GlaxoSmithKline plc 121
Johnson & Johnson 125
Merck & Co. 127
Moderna Inc. 129
Novavax, Inc. 130
Pfizer Inc. 132
Sanofi SA 136
Takeda Pharmaceutical Co. Ltd. 139
RELATED REPORTS 141
List of Tables:
Table 1. Snapshot of Asia Pacific Preventive Vaccines Market in Balanced Perspective, 2022-2032 18
Table 2. World Economic Outlook, 2021-2031 23
Table 3. World Economic Outlook, 2021-2023 24
Table 4. Scenarios for Economic Impact of Ukraine Crisis 28
Table 5. World Health Spending by Region, $ bn, 2013-2020 36
Table 6. Main Product Trends and Market Opportunities in Asia Pacific Preventive Vaccines Market 40
Table 7. Asia Pacific Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 48
Table 8. Asia Pacific Preventive Vaccines Market by Disease, 2022-2032, $ mn 58
Table 9. Asia Pacific Preventive Vaccines Market by Administration, 2022-2032, $ mn 69
Table 10. Asia Pacific Preventive Vaccines Market by Patient, 2022-2032, $ mn 76
Table 11. Asia Pacific Preventive Vaccines Market: Pediatric Vaccines by Disease, 2022-2032, $ mn 79
Table 12. Asia Pacific Preventive Vaccines Market: Adult Vaccines by Disease, 2022-2032, $ mn 81
Table 13. APAC Preventive Vaccines Market by Country, 2022-2032, $ mn 83
Table 14. Japan Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 87
Table 15. Japan Preventive Vaccines Market by Disease, 2022-2032, $ mn 87
Table 16. Japan Preventive Vaccines Market by Administration, 2022-2032, $ mn 88
Table 17. China Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 90
Table 18. China Preventive Vaccines Market by Disease, 2022-2032, $ mn 90
Table 19. China Preventive Vaccines Market by Administration, 2022-2032, $ mn 92
Table 20. Australia Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 94
Table 21. Australia Preventive Vaccines Market by Disease, 2022-2032, $ mn 94
Table 22. Australia Preventive Vaccines Market by Administration, 2022-2032, $ mn 95
Table 23. India Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 97
Table 24. India Preventive Vaccines Market by Disease, 2022-2032, $ mn 97
Table 25. India Preventive Vaccines Market by Administration, 2022-2032, $ mn 98
Table 26. South Korea Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 100
Table 27. South Korea Preventive Vaccines Market by Disease, 2022-2032, $ mn 100
Table 28. South Korea Preventive Vaccines Market by Administration, 2022-2032, $ mn 101
Table 29. Preventive Vaccines Market in Rest of APAC by Country/Region, 2022-2032, $ mn 103
Table 30. AstraZeneca plc: Company Snapshot 108
Table 31. AstraZeneca plc: Business Segmentation 109
Table 32. AstraZeneca plc: Product Portfolio 109
Table 33. Bavarian Nordic A/S: Company Snapshot 110
Table 34. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 111
Table 35. China National Biotec Group Company Ltd.: Company Snapshot 113
Table 36. CSL Ltd.: Company Snapshot 115
Table 37. Daiichi Sankyo Co. Ltd.: Company Snapshot 117
Table 38. Emergent BioSolutions Inc.: Company Snapshot 119
Table 39. GlaxoSmithKline: Company Snapshot 121
Table 40. GlaxoSmithKline: Business Segmentation 122
Table 41. GlaxoSmithKline: Product Portfolio 123
Table 42. GlaxoSmithKline: Revenue, 2018-2020, $ bn 124
Table 43. GlaxoSmithKline: Recent Developments 124
Table 44. Johnson & Johnson: Company Snapshot 125
Table 45. Johnson & Johnson: Business Segments 126
Table 46. Merck & Co., Inc.: Company Snapshot 127
Table 47. Merck & Co., Inc.: Business Segmentation 127
Table 48. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 128
Table 49. Moderna Inc.: Company Snapshot 129
Table 50. Novavax, Inc.: Company Snapshot 130
Table 51. Pfizer Inc.: Company Snapshot 132
Table 52. Pfizer Inc.: Business Segmentation 133
Table 53. Pfizer Inc.: Product Portfolio 134
Table 54. Pfizer Inc.: Revenue, 2018-2020, $ bn 135
Table 55. Pfizer Inc.: Recent Developments 135
Table 56. Sanofi: Company Snapshot 136
Table 57. Sanofi: Business Segmentation 136
Table 58. Sanofi: Revenue, 2018-2020, $ bn 138
Table 59. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 139
